Markets & Investing
Tom McDonald, CEO of Clerkenwell Health, Sits in the Investor Hotseat on March 30th
During this edition of the Investor Hotseat, host Dustin Robinson of Iter Investments is joined by Tom McDonald of Clerkenwell Health. Clerkenwell Health…
During this edition of the Investor Hotseat, host Dustin Robinson of Iter Investments is joined by Tom McDonald of Clerkenwell Health.
Clerkenwell Health is a leading psychedelic specialty CRO offering specialist trial design, regulatory submission, and trial delivery services.
Tom’s background is in the biopharmaceutical sector including 18 months at IQVIA (formerly Quintilles-IMS, the world’s largest CRO) alongside experience across 5 of the global top 10 pharma companies.
How will Tom handle the hot seat? Tune in to find out.
As always, this will be a live event. You’ll be able to stream it from the Psychedelic Invest website, YouTube, LinkedIn, Facebook, Twitch, and Twitter. If you miss it, though, don’t worry. It will be recorded and available across those channels after the event.
If you’d like to attend the live event, you can set a reminder on Youtube or LinkedIn. Or, you can return to the Hotseat livestream page at the time of the event.
To RSVP to ensure your spot, please fill out the form below.
A Transcription Will Be Available Following the Event
-
Psychedelics1 week agoCybin Announces Grant of Additional U.S. Patent in Support of its CYB003 Breakthrough Therapy Program for Major Depressive Disorder
-
Law & Regulation1 week agoGoing concern warnings cloud Xtacy Therapeutics’ shrunk losses
-
Psilocybin1 week agoAre Shrooms Legal in Oregon: Full Guide
-
Psychedelics1 week agoOptimi Health Achieves Milestone: Completes In-House Production of MDMA Active Pharmaceutical Ingredient (API)
-
Psychedelics1 week agoAtai Life Sciences Announces the Publication of Beckley Psytech’s Phase 1 Study of BPL-003 in the Journal of Psychopharmacology
-
Psychedelics1 week agoPsyence Group’s NASDAQ Listed Associate, Psyence Biomedical Partners with Fluence and iNGENū CRO to Train Research Therapists for Phase IIb Psilocybin Trial
-
Law & Regulation1 week agoClearmind signs agreement with Hebrew University for psychedelic compound rights
-
Psychedelics6 days agoPsychedelics Can Offer More Than Therapy On Its Own